🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Teriparatide

    United Therapeutics Europe Ltd

    Stress Fracture

    phase 3 small molecule active

    1 trial

  2. Testosterone Gel 1%, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Bomba de gel transparente, donde la sustancia activa (testosterona) fue sustituida por agua purificada.

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    phase 3 small molecule active

    1 trial

  3. Testosterone enanthate

    HALOZYME THERAPEUTICS, INC.

    Hypogonadism, Male

    phase 3 other active

    1 trial

  4. Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo

    AstraZeneca AB

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    phase 3 small molecule active

    1 trial

  5. Thalidomide

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  6. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  7. The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  8. The Placebo Nebuliser Solution is a solution dosage form for nebulisation identical to Treprostinil Nebuliser Solution drug product except for the absence of the treprostinil drug substance., Treprostinil

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  9. The methylprednisolone sodium succinate

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  10. The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.

    Lacuna Pharma Pty Ltd

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  11. The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα

    Lacuna Pharma Pty Ltd

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

  12. The placebo product consists of a soft capsule similar to the ones containing the active substance, VESSEL® 250 ULS capsule molli

    Fondazione Telethon ETS

    Prevention of recurrence after a first episode of Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  13. The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.

    Lacuna Pharma Pty Ltd

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  14. The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  15. Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  16. Tiaoshen Anti-cancer Granules

    The First People's Hospital of Lianyungang

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  17. Tibsovo 250 mg film-coated tablets

    The George Institute

    ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  18. Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine

    United Therapeutics Europe Ltd

    COVID-19

    phase 3 small molecule terminated

    1 trial

  19. Tinidazole oral microneedle patch

    The First People's Hospital of Lianyungang

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  20. Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  21. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  22. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  23. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  24. Tobramycin Injection

    United Therapeutics Europe Ltd

    Wound Infection

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources